203. 22q11.2 deletion syndrome Clinical trials / Disease details

Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002011-61-NL (EUCTR)	13/08/2021	21/06/2021	Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome	The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11 ...	22q11.2 deletion syndrome;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]	Trade Name: Rilutek Product Name: Riluzole Product Code: EMEA/H/C/000109	Academisch ziekenhuis Maastricht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	Netherlands
2	NCT05149898 (ClinicalTrials.gov)	March 3, 2020	5/10/2021	Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children ...	Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children ...	22Q Deletion Syndrome	Drug: ZYN002	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	4 Years	17 Years	All	20	Phase 1/Phase 2	United States;Australia
3	NCT04639960 (ClinicalTrials.gov)	September 29, 2017	3/11/2020	Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome	Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes ...	22q11.2 Deletion Syndrome	Drug: Risperdal;Drug: Placebo	University of Geneva, Switzerland	NULL	Recruiting	11 Years	25 Years	All	30	N/A	Switzerland
4	NCT02895906 (ClinicalTrials.gov)	November 28, 2016	29/8/2016	Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsy ...	A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged ...	22q11.2 Deletion Syndrome	Drug: NFC-1	Aevi Genomic Medicine	NULL	Completed	12 Years	17 Years	All	2	Phase 1	United States
5	NCT04647500 (ClinicalTrials.gov)	August 26, 2016	3/11/2020	Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome	Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Proce ...	22q11.2 Deletion Syndrome	Drug: Concerta	University of Geneva, Switzerland	NULL	Recruiting	8 Years	25 Years	All	30	N/A	Switzerland

First Previous1Next Last